GALE


Stock Update (NASDAQ:GALE): Galena Biopharma Inc Presents GALE-401 (Anagrelide Controlled Release) Phase 2 Data at the European Hematology Association 20th Congress

Galena Biopharma Inc (NASDAQ: GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum …

Galena Biopharma Inc (GALE)’s Bullish Stance Reiterated at Maxim Ahead of ASCO Meeting

Maxim’s healthcare analyst Jason Kolbert weighed in today with a favorable report on Galena Biopharma Inc (NASDAQ:GALE), after the company reported the presentation of two abstracts at …

Company Update (NASDAQ:GALE): Galena Biopharma Inc Announces Publication of Two Abstracts at the 2015 American Society of Clinical Oncology Annual Meeting

Galena Biopharma Inc (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of …

Company Update (NASDAQ:GALE): Galena Biopharma Inc to Present GALE-401 Phase 2 Clinical Trial Data at the European Hematology Association 20th Congress

Galena Biopharma Inc (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of …

Stock Update (NASDAQ:GALE): Galena Biopharma Inc Reports First Quarter 2015 Financial Results

Galena Biopharma Inc (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of …

Stock Update (NASDAQ:GALE): Galena Biopharma Inc Completes Over-Enrollment of NeuVax(TM) (nelipepimut-S) Phase 3 PRESENT Clinical Trial

Galena Biopharma Inc (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum …

Stock Update (NASDAQ:GALE): Galena Biopharma Inc Announces Closing of Over-Allotment Option, Increasing Total Gross Proceeds to $43.7 Million

Galena Biopharma Inc (Nasdaq:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of …

MLV Reiterates Buy on Galena Biopharma Inc Following Enrollment Expansion of NeuVax Combo Phase 2b

MLV’s healthcare analyst Vernon Bernardino came out with a few insights on Galena Biopharma Inc (NASDAQ:GALE), after the company announced expansion of targeted patient population for its ongoing …

Company Update (NASDAQ:GALE): Galena Biopharma Inc Expands Patient Population in NeuVax(TM) (nelipepimut-S) and trastuzumab Phase 2b Combination Clinical Trial in HER2 1+/2+ Patients

Galena Biopharma Inc (NASDAQ:GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer …

MLV Pounds the Table on Galena Biopharma Inc

MLV analyst Vernon Bernardino was out pounding the table on Galena Biopharma Inc (NASDAQ:GALE) Monday, reiterating a Buy rating and a $5 price target, …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts